Ventricular Assist Device – Miniature

The treatment of individuals with severe heart failure has been transformed by the development of a ventricular assist device (VAD). When a donor heart cannot be identified, the VAD, which was initially designed as a bridge to transplantation, has been proved to extend life and improve quality of life. Older models needed patients to ambulate with hefty, huge external batteries and control devices and required the implantation of a big pump. Yet in the upcoming years, a number of ground-breaking advancements in device size, battery life, and even wireless charging technologies may render these devices physically undetectable and possibly reduce patient vulnerability to infections. The rates of haemolysis, thrombosis, and secondary aortic valve insufficiency have also been constrained by numerous mechanical improvements and newer operating paradigms.

Cardiac Decellularization and Engineered Heart Tissue

Promising new directions in cardiovascular research are tissue engineering techniques that use cells and regenerative medicine to treat heart problems. For the reconstruction of new tissue to be possible, scaffolds (i.e., biomaterials used as supports), cells, and suitable growth factors are required. Making the perfect scaffold remains one of the most difficult aspects of tissue engineering since the biomaterial is essential to the functional integrity and adhesion of human cells. The complex, distinctive, and organic structure that a decellularized heart made of native extracellular matrix can supply can deliver the physical and chemical signals necessary for cardiac activity.

Engineered Heart Valve

Heart valve abnormalities, whether congenital or acquired, have a significant global impact. Despite these drawbacks, mechanical or bioprosthetic replacement valves are frequently used. Particularly for pediatric patients who are still developing, this is true. Creating an in situ tissue engineering strategy is one potential fix. A synthetic, biodegradable scaffold could result in the creation of custom heart valve replacements. These might be healthier for pediatric populations and less prone to infections.

To know more information visit https://www.cardiology.scientexconference.com/


Comments

Post a Comment

Popular posts from this blog

Image
Myocardial infarction events involving morality, incredibly high temperatures, and minute particles.  Myocardial infarction (MI) morbidity has been connected to extreme temperature events (ETEs), such as heat wave and cold spell, but their effects on MI mortality are less well understood. Although ambient fine particulate matter (PM2.5) and severe temperatures may work in concert to increase cardiovascular mortality , it is still unclear whether or how ETEs and PM2.5 interact to cause MI deaths.METHODS: To examine the relationship between exposure to ETEs and PM2.5 and MI mortality and assess their interacting effects, a time-stratified case-crossover study of 202 678 MI deaths in Jiangsu province, China, from 2015 to 2020 was conducted. Twelve ETE definitions were created using a variety of temperature thresholds and durations based on the perceived ambient temperature. In order to estimate daily ETEs and PM2.5exposures , values were taken from validated grid datasets at reside...
Read more

New Drug Nearly Eradicates “Stealth” Cholesterol (Lp(a)) – A Game‑Changer in Heart Disease Prevention

Image
A recent clinical trial reported in the New England Journal of Medicine and showcased at the American College of Cardiology revealed that lepodisiran—an experimental RNA-targeting drug—can reduce lipoprotein(a) [Lp(a)] by nearly 100% after a single dose, with sustained effects over a year 🔍 What You Need to Know Lp(a) is a genetically determined, stealth cholesterol that significantly raises the risk of heart attacks and strokes yet is not addressed by diet or standard statins. The Phase 2 trial, involving 320 participants across 10 countries, showed almost total Lp(a) suppression at 6 months, maintained at 1 year. Reported side effects were mild, primarily limited to injection-site reactions. No serious safety issues were found.                      🌍 Why This Matters This breakthrough could pave the way for targeted Lp(a) therapies—potentially reducing cardiovascular risk in over 1.4 billion people globally with elevated levels....
Read more